Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market to Reach 12.28 Trillion Yen by FY2029: IQVIA
June 25, 2025
- Novartis Taps Cancer Institute Hospital as Priority Trial Site in Japan
June 25, 2025
- FDA Approves Daiichi’s Datroway for EGFR Lung Cancer
June 25, 2025
- Medipal/JCR’s MPS IIIB Therapy Earns Orphan Status in Europe
June 25, 2025
- Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
- Axcelead, Superluminal Pair Up to Target Challenging Molecular Mechanisms
June 24, 2025
- Otsuka Bags Rights to Bispecific T-Cell Engager from China’s Harbour
June 24, 2025
- Ono Snags Japan, Korea Rights to Vertex’s Povetacicept
June 24, 2025
- GMP Deviation at CMO Katsuyama Caused Viatris Shipment Halt
June 23, 2025
- Boehringer to Invest 300 Million Euros in New Facilities at Yamagata Plant
June 23, 2025
- GSK’s RSV Vaccine Arexvy Filed for High-Risk Adults Aged 18-49 in Japan
June 23, 2025
- Moderna Files Next-Gen COVID Vaccine in Japan
June 23, 2025
- SanBio, Minaris Aim to Expand Global Reach of Akuugo
June 20, 2025
- Japan Rare Disease Drug Market to Grow Nearly 70% by 2040: Fuji Keizai
June 20, 2025
- Viatris Pauses Shipments of Polyful, Other Drugs over Manufacturing Issues
June 20, 2025
- Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
June 20, 2025
- Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
June 20, 2025
- NEC Reports Positive Results in AI Demo for Predicting Cancer Drug Combos
June 19, 2025
- Axcelead, Lotte, Kanaph Join Forces to Push ADCs
June 19, 2025
- Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…